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Abstract
Purpose: The present study investigated the levels of circulating cell-free DNA (cfDNA) in plasma from
patients with metastatic colorectal cancer (mCRC) in relation to third-line treatment with cetuximab and
irinotecan and the quantitative relationship of cfDNA with tumor-specific mutations in plasma.
Experimental Design: Inclusion criteria were histopathologically verified chemotherapy-resistant
mCRC, adequate Eastern Cooperative Oncology Group performance status, and organ function. Treatment
consisted of irinotecan being administered at 350 mg/m2 for 3 weeks and weekly administration of
250mg/m2 cetuximabuntil progressionorunacceptable toxicity. Aquantitative PCRmethodwasdeveloped
to assess the number of cfDNA alleles and KRAS and BRAF mutation alleles in plasma at baseline.
Results: The study included 108 patients. Only three patients were positive for BRAF mutations. The
majority of KRAS mutations detected in tumors were also found in the plasma [32 of 41 (78%)]. Plasma
cfDNA and plasmamutantKRAS levels (pmKRAS) were strongly correlated (r¼ 0.85, P < 104). The disease
control rate was 77% in patients with low cfDNA (<25% quartile) and 30% in patients with high cfDNA
[>75%quartile (P¼ 0.009)]. Patients with pmKRAS levels higher than 75%had a disease control rate of 0%
compared with 42% in patients with lower pmKRAS (P ¼ 0.048). Cox analysis confirmed the prognostic
importance of both cfDNA and pmKRAS. High levels were clear indicators of a poor outcome.
Conclusions: KRAS analysis in plasma is a viable alternative to tissue analysis. Quantitative levels
of cfDNA and pmKRAS are strongly correlated and hold promise of clinical application. Clin Cancer Res;
18(4); 1177–85. 2012 AACR.
Introduction
The overall outcome of metastatic colorectal cancer
(mCRC) has been improved by the use of monoclonal
antibodies (mAb) targeting the epidermal growth factor
receptor (EGFR), but thesedrugs are associatedwitha specific
toxicity profile along with major costs (1–5). The intensive
search for predictive and prognostic markers in this setting
has successfully identified downstream KRAS and BRAF
mutations as responsible for tumor resistance to treatment
(6–8). A recentmeta-analysis investigated 22 studies, includ-
ing 2,188 patients who were treated with anti-EGFR mAbs
and concluded that overall KRAS mutational status was
associated with lack of response, shorter progression-free
survival (PFS), and overall survival (OS; ref. 9). Thus, the
emerging data on the association between KRASmutational
status and nonresponsiveness have led to restriction of the
use of these drugs for patients with wild-type KRAS
(WTKRAS) only. BRAF mutational status has not yet been
established as a selection criterion but seems to be equally
important to the outcome, although less frequent. However,
colorectal tumors are known to be heterogeneous in nature,
which is illustrated by the fact that approximately 60%of the
patients withWTKRAS fail to achieve a radiological response
to EGFR inhibitors. Even more intriguing, a subgroup of
patients hosting KRASmutant disease achieves a prolonged
stabilization of the disease. Therefore, additional reliable
markers for outcome are still needed.
In general, KRASmutations are considered an early event
in colorectal carcinogenesis, and the use of tissue from the
primary tumor for pretreatment testing has been accepted as
a basis for treatment of metastatic diseases (10–12). How-
ever, the absence of detectable mutations in the primary
tumor cannot formally exclude the presence of mutant
metastatic diseases. Tumor heterogeneity and mutational
selection during disease progression are aspects that need
further elucidation (13,14). Unfortunately, metastatic
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tissue is rarely available for testing because of practical and
ethical reasons, and alternative methods for mutational
testing can be of great clinical value.
The presence of circulating nucleic acids in plasma and
serum of patients with cancer was identified more than 60
years ago, and studies have suggested predictive and prog-
nostic roles in different settings, including CRC (15, 16).
However, results have not been translated into clinical prac-
tice, but efforts during the last decade have led to significant
progress in the development of highly sensitive and repro-
ducible methods (17). The factors influencing the quantita-
tive aswell asqualitative changesof cell-freeDNA(cfDNA) in
patients with cancer are multiple and not yet fully explored,
but a substantialproportionofcirculatingcfDNAinplasmais
believed to originate from tumor cells and can, therefore, be
tested for tumor-specific genetic alterations such as KRAS or
BRAF mutations (18, 19). Clearly, this opens up for inves-
tigations of a number of highly relevant issues such as
methodology, correlation to clinical outcome, dynamic
changes of mutational status during EGFR inhibitor treat-
ment, and potential solutions of practical issues.
We have developed a highly sensitive method to analyze
plasma samples for cfDNAwithKRASorBRAFmutations in
patients with CRC with chemotherapy-resistant metastatic
disease during treatment with third-line cetuximab and
irinotecan. The purpose was to assess the correlation
between baseline plasma and tumor mutational status and
to investigate the predictive and prognostic value of quan-
titative estimates of cfDNA and plasma mutant KRAS
(pmKRAS) at baseline.
Patients and Methods
Patient material
A prospective biomarker study was conducted at Depart-
ment of Oncology, Vejle Hospital, to investigate predictive
and prognostic markers in third-line treatment with cetux-
imab and irinotecan for mCRC. Inclusion criteria were
histopathologically verified mCRC, treatment failure after
exposure to fluoropyrimidine, oxaliplatin, and irinotecan,
indication for third-line treatment with cetuximab and
irinotecan, Eastern Cooperative Oncology Group (ECOG)
performance status (PS) 0 to 2, and adequate organ func-
tion. Treatment consisted of irinotecan 350 mg/m2 every 3
weeks combinedwithweekly cetuximab 250mg/m2 (initial
loading dose was 400mg/m2). Archival paraffin-embedded
tissue samples from primary tumor and/or metastatic tis-
sues were collected and blood samples for marker analysis
were drawn at baseline prior to cycle one. Response and
toxicity were evaluated according to Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.0 and Com-
monTerminologyCriteria for Adverse Events (CTC) version
3.0, respectively. Response evaluation was conducted every
9 weeks with clinical and radiological examination by
computed tomographic scan of the chest and abdomen
and/or magnetic resonance scan. Patients were classified as
having complete response (CR), partial response (PR),
stable disease (SD), or progressive disease (PD). Only
patients with CR and PR could be classified as responders,
whereas those with SD and PD were defined as nonrespon-
ders. Disease control (DC) included patients who achieved
a response or SD. The study was conducted in accordance
with the Danish law after approval by the Regional Ethics
Committee. Written informed consent was obtained from
all patients.
Sample collection and DNA purification
Formalin-fixed, paraffin-embedded (FFPE) tumor tissue
was evaluated histologically by a dedicated pathologist to
confirm the number of viable tumor cells. In some cases, a
microdissection was carried out to increase the percentage
of tumor cells. Three 15-mm tissue sections were deparaffi-
nated by xylene and ethanol extractions and subjected to a
proteinase K digestion overnight at 56C. DNA was then
purified using a QIAamp DNAMini kit (Qiagen) according
to the manufacturer’s recommendations.
A 9-mL peripheral blood sample was collected in EDTA
tubes from patients at baseline (i.e., before starting third-
line chemotherapy). After collection, plasma was obtained
by centrifugation at 2,000 g for 10minuteswithin 2 hours
and stored at 80C until use.
Total nucleic acid was purified from 1.2 mL plasma
using a QIAsymphony virus/bacteria midi-kit on a QIA-
symphony robot (Qiagen) according to the manufac-
turer’s instructions. Plasma samples with inadequate
plasma volume were added to 1.2 mL water prior to
purification. Because both DNA and RNA were copur-
ified and plasma DNA is fragmented, often as multiples
of 180 bp, the amount and integrity of DNA were
determined functionally by quantitative PCR (qPCR)
using an in-house assay for the housekeeping gene cyclo-
philin (gCYC; which is a gene not known to be involved
in cancer) through amplification of a 132-bp PCR frag-
ment (Supplementary Table S5). The gCYC qPCR results
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were used to normalize plasma sample DNA to number
of DNA alleles per mL.
KRAS mutational analysis
KRAS analysis of primary tumor and metastases was
conducted using a KRAS DxS kit (Qiagen) according to the
manufacturer’s recommendations, as previously published
(12). Primers and probes for in-house KRAS and BRAF
assays as well as KRAS mutation control PCR fragments
were generated by site-directed mutagenesis (Supplemen-
tary Fig. S5 and Tables S5 and S6)with the use of theOLIGO
7 software (Molecular Biology Insights Inc.). The in-house
assays use an amplification refractory mutation system
qPCR (ARMS-qPCR) methodology and detect 6 mutations
in KRAS codon 12 (Gly12Ala, Gly12 Arg, Gly12Asp,
Gly12Cys, Gly12Ser, and Gly12Val), one mutation in
codon 13 (Gly13Asp), and the most frequent BRAF muta-
tion (V600E).
A number of refractory primers were tested on DNA
samples from patients with mutation-positive colorectal
cancer as well as normal donor DNA. To increase the
specificity of the qPCR reactions, a wild-type blocking
oligo was added in some reactions. The blocking oligos
were modified by including HyNA nucleotides (Penta-
base ApS), which increased the melting temperature and
blocked extension. The final primer mixtures resulting in
amplicon lengths between 118 and 122 bp are shown in
Supplementary Table S5. All qPCR reactions were carried
out in a volume of 25 mL in duplicates on an ABI
Prism7900HT (Applied Biosystems) using ABI Universal
Mastermix with UNG (Applied Biosystems). In all assay
rounds, a mixture of patient samples containing DNA that
represented all mutations was included as positive con-
trols. Water controls and wild-type donor DNA controls
were used as negative control. The qPCR reaction condi-
tions were 2 minutes at 50C and 10 minutes at 95C,
followed by 50 cycles of 15 seconds at 95C and 60
seconds at 60C.
Validation of the in-house assays
The in-house KRAS assay was validated on 294 FFPE
ovarian cancer samples, where KRAS analysis had been
conducted using the KRAS DxS Kit (Qiagen). Nineteen of
these samples had a poor quality DNA or lacked DNA and
were not included in the study. Analysis of the remaining
275 samples showed a 100% concordance between the
DxS Kit and the in-house KRAS assay (20). The stability
and reproducibility of the in-house KRAS assays were
validated over a 4-month period on 3 mixtures of DNA
sample of patients with FFPE CRCs containing the 7 KRAS
mutations. As shown in Supplementary Fig. S6, the assay
showed very little variation. The in-house BRAF V600E
assay was validated on the primary CRC tumors and a
100% agreement with the results of the DxS Kit was
revealed. In addition, 40 FFPE colorectal tumor samples,
which were BRAF V600E positive when analyzed by
Sanger sequencing, were all positive with the in-house
BRAF assay.
Positive controls by KRAS site-directed PCR
mutagenesis
To obtain unlimited amounts of positive controlmaterial
for the KRAS assay, a site-directed PCRmutagenesis strategy
was used. Seven PCR products of 381 bp were generated,
each carrying a KRAS mutation, (Supplementary Table S6)
and were used to generate standard curves.
Quantification of cfDNA and KRAS in plasma
Standard curves were generated by spiking dilutions of
KRAS site-directed mutated PCR product in 5-fold decre-
ments into 100 ng normal donor DNA (pool of DNA
purified from normal blood samples). For BRAF, similar
spikingswere carried out usingDNA from theBRAFV600E–
mutated colorectal adenocarcinoma cell line HT29
(DSMZ). From the standard curves, the slopes were calcu-
lated for the gCYC (3.4), KRAS (3.4–3.6), and BRAF V600E
(3.4) primer sets (Supplementary Fig. S4A). The y-intercept
corresponding to one DNA copy of the target DNA was
estimated and set to a cycle threshold (Ct) of 41 (gCYC and
BRAF) or 41 to 42 (KRAS) using a threshold of 0.2. The
specificity of the different in-house assays were tested in 100
ng normal donor DNA using gCYC as reference and from
the standard curves calculated to 0.025% for Gly13Asp,
0.004% for Gly12Ser, and better than 0.001% for Gly12Ala,
Gly12Arg, Gly12Asp, Gly12Cys, Gly12Val, and BRAF
V600E, (Supplementary Fig. S4B). However, for routine
use, the maximum sensitivity of the assays was set to 10-
fold less than the specificity. For all KRAS mutation–neg-
ative samples, the number of DNA alleles was calculated
from the internal positive control (WTKRAS for DxS, gCYC
for the in-house KRAS assay, and WTBRAF for V600E), and
the sensitivity of a negative sample was determined by what
was reached first: the allele number or the maximum
sensitivity. In samples with a low allele number, this num-
ber was compared with the number of tumor cells found by
the pathologist, and if the alleles were less than 10-fold
higher than the percentage of tumor cells, the sample was
considered nonconclusive.
Quantification of cfDNA was done by calculating
the copy number of gCYC alleles as
10 yintercept gCYCð ÞmeanCt gCYCð Þ½ =slope gCYCð Þf g and normaliz-
ing this to the plasma volume. Quantification of KRAS was
done by calculating the copy number of mutated KRAS
alleles as 10 yintercept KRASð ÞmeanCt KRASð Þ½ =slope KRASð Þf g and
normalizing this to the plasma volume. Similarmethodwas
used to quantify the BRAF mutations.
The high specificity of this new qPCR assay enables
detection of KRAS or BRAFmutations in a high background
of normal DNA, which is not achieved with other methods
such as Sanger or next-generation sequencing.
Statistics
The association between marker status and objective
response rates, baseline characteristics, and skin toxicity
rates was determined by Wilcoxon rank-sum or c2 test,
where appropriate. The correlation between cfDNA and
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pmKRAS alleles was investigated with Spearman rank cor-
relation. Patients who reached the first objective tumor
evaluation after 3 cycles or experienced clinical progression
prior to this point were considered evaluable for response
according to RECIST. PFS was defined as the time from start
of the treatment until documented tumor progression or
death. OS was calculated from the date of first treatment
until death by any course. Survival analyses were conducted
according to the Kaplan-Meier method, and PFS and OS
curves were compared by log-rank test. A multivariate Cox
regression analysis was conducted using a backward step-
wise elimination process, which eliminates the predictor
with the largest P value in each step until all predictors in the
final model had P < 0.2. The proportional hazards assump-
tion was tested by visual inspection of the log[log
(survival)] versus log(time) curves. Two-sided P values were
considered significant when P  0.05. (No correction for
multiple testing was applied.) Statistics were carried out
using the NCSS Statistical Software 2007 v.07.1.5 (NCSS
Statistical Software; www.ncss.com) except the test of the
proportional hazards assumption, which was conducted in
SPSS v. 15.0.
Results
Patient characteristics
Patients’ baseline characteristics have been listed
in Table 1. The study included patients during the period
of April 2005 until April 2008. The median follow-up was
7 months and ended by November 2010. The median
number of cycles was 3.4 (range, 0–21). Three patients
deteriorated before receiving the first cycle and were not
treated. Four patients commenced the first cycle but
stopped because of an anaphylactic reaction (3) or
patient’s wish (1). Consequently, 7 of the patients were
not evaluable for response according to RECIST but were
still included in survival analysis according to intention to
treat. Seventeen patients having received at least one cycle
of treatment showed clinical progression before the first
evaluation scan and were subsequently included in anal-
ysis as having PD. The rate of PR was 20% (20 of 101), SD
34% (34 of 101), and PD 47% (47 of 101). Outcome
according to mutational status was previously presented
(12).
Correlation between KRAS status in tissue and plasma
A total of 98 patients had primary tissue available for
mutational testing. All patients hadblood samples available
for testing, but the analysis showed inconclusive results in 3
cases, leaving 95 assessable for comparison of tissue anal-
yses and peripheral blood (Table 2). The majority of KRAS
mutations detected in the tumor were also found in the
peripheral blood; 32 of 41 (78%). Interestingly, one of the
patients had a primary KRAS mutant tumor, but wild-type
metastatic disease, which was confirmed in the peripheral
blood. Unfortunately, nometastatic tissue was available for
testing in the remaining 8 patients with disconcordant
results. Of note, none of the patients without mutations
detected in the primary tumor tissue were tested positive in
the baseline plasma sample.
Quantitative baseline levels of cfDNA, KRAS, and BRAF
alleles in plasma
As presented in Fig. 1, there was a clear correlation
between the level of KRAS mutations and cfDNA in the
plasma (Spearman rank correlation, 0.85; P < 0.0001). The
median level of cfDNA was 23,000 alleles per mL plasma
(range, 2,000–4,616,000). There was no significant differ-
ence in the levels of cfDNA between patients with KRAS
mutant (median, 19,500; range, 2,000–4,600,000) and
wild-type disease (median, 25,000; range, 2,600–
610,000; P > 0.05). The median level of pmKRAS was
3,300 (range, 50–180,000). Only 2 patients revealed BRAF
mutation alleles in the plasma and consequently, no further
analysis was conducted. The median levels of cfDNA and
pmKRAS were tested against baseline characteristics and
showed a significantly higher level with poor PS and a
tendency of correlation to the number of metastatic sites
Table 1. Patients' baseline characteristics
Parameter n (%), N ¼ 108
Age, y
Median (range) 62 (38–82)
Gender
Female 48 (44)
Male 60 (56)
PS at inclusion
0 55 (51)
1 42 (39)
2 9 (8)
ND 2 (2)
Locus primary tumor
Rectum 35 (32)
Colon 70 (65)
ND 3 (3)
Number of metastatic sites at inclusion
1–2 56 (52)
>2 49 (45)
ND 3 (3)
Number of CT regimens
3 27 (25)
2 78 (72)
ND 3 (3)
Previous surgery for primary
Yes 97 (90)
No 8 (7)
ND 3 (3)
Previous radiotherapy for primary
Yes 15 (14)
No 88 (81)
ND 5 (5)
Abbreviations: CT, chemotherapy; ND, not determined.
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prior to treatment, whereas all other parameters showed
nonsignificant differences. This suggested that PS and dis-
ease status possibly influence the level of cfDNA in the
peripheral circulation. The median cfDNA in PS 0 patients
was 15,000 alleles permLplasma (range, 2,000–1,000,000)
and 52,000 alleles per mL plasma (range, 14,000–420,000)
in patients with PS 2 at baseline; P¼ 0.03 (not corrected for
multiple comparisons).
Baseline cfDNA levels and correlation to tumor
response
There was a significant difference between the groups of
patients who achieved DC (29,600 alleles per mL plasma)
and those who progressed early (130,000 alleles per mL
plasma). The DC rate decreased with increasing level of
cfDNA in the plasma, as shown in Table 3. The DC rate was
77% in patients with low cfDNA (<25%) compared with
30% in patients with high levels [>75% (P ¼ 0.009)]. A
descriptive receiver-operating curve analysis was conducted
to test the performance of cfDNA for predicting disease
stabilization. The area under the curve was 0.69 [95%
confidence interval (CI), 0.56–0.77; P < 0.001]. A cutoff
point at the 75% level of cfDNA carriedoutwith a sensitivity
of 87%, whereas the 90% produced a sensitivity of 96% for
early disease progression.
Baseline pmKRAS levels and tumor response
The patients with high pmKRAS levels (>75%) had a DC
rate of 0% compared with 42% in patients with low
pmKRAS levels (<75% percentile; P ¼ 0.048).
The prognostic value of baseline cfDNA levels
Patients with cfDNA levels below the median had a
median OS of 12.2months (95%CI, 10.2–13.9) compared
with 4.5 months (95% CI, 3.9–5.5) in those with high
levels; P <0.001. The PFSwas 5.7months (95%CI, 4.1–6.9)
and 2.2 months (95% CI, 2.1–2.8), respectively; P < 0.001.
The Kaplan–Meier survival curves according to baseline
cfDNA are shown in Fig. 2, which also includes survival
analysis according to pmKRAS. In brief, an unfavorable
survival time was revealed with increasing baseline levels of
cfDNA and pmKRAS.
For the initial multivariate Cox regression analysis, we
included ECOG PS and cfDNA quartiles (values 1–4) as
numeric predictors and pretreatment KRAS mutational
status, respectively, and number of metastatic sites at
baseline, age, gender, and tumor location as categorical
predictors. By entering PS and cfDNA quartile as numeric
predictors in the Cox model, we implicitly assume linearity
of the effect on a log-risk scale. The inclusion of quadratic
terms did not improve the model, thus supporting the
validity of the linearity assumption. Furthermore, we con-
ducted separate multivariate analyses by entering cfDNA as
Table 2. Comparison of KRAS detection in
tissue and plasma
Tumor KRAS
mutation
Tumor
WTKRAS Total
Plasma KRAS
mutation
32 0 32
Plasma WTKRAS 9 54 63
Total 41 54 95
NOTE: Sensitivity, 78%; speciﬁcity, 100%; positive predic-
tive value, 100%; negative predictive value, 86%.
Figure 1. Correlation between
concentrations of KRAS mutations
and cfDNA in plasma. KRAS
mutational alleles per mL plasma are
plotted against the number of cfDNA
alleles per mL plasma. Because of
the broad range of values, a
logarithmic scale was used. The
Spearman rank correlation was 0.85;
P < 0.0001.
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a dichotomized covariate (above vs. below median and
above vs. below75%percentile), both ofwhich retained the
highly significant correlation to outcome (data not
shown). Table 4 shows the final model for PFS and OS
after the stepwise elimination process. cfDNA remained a
strong prognostic factor for PFS and OS when analyzed as
numeric variable in quartiles.However, using themedianor
75% as cutoff point did not alter the highly significant
correlation to outcome (data not shown). A multivariate
model built using cfDNA quartiles and the established
prognostic markers of KRAS status, number of metastatic
sites, and age yielded HRs of 1.4 (95% CI, 1.1–1.7) and 1.8
(1.4–2.2) for cfDNA quartiles and PFS andOS, respectively.
Quantitative levels of pmKRAS were not entered in the
model because the sample size for KRAS mutant patients
was limited to 35 patients and a strong correlation to cfDNA
Table 3. Correlation between DC and plasma marker levels
Best response Total <25% Q 25%–50% Q 50%–75% Q >75% Qa
Quantitative cfDNA levels in plasma
DC 52 20 (77%) 14 (56%) 11 (44%) 7 (30%) P ¼ 0.004
PD 47 6 (23%) 11 (44%) 14 (56%) 16 (70%)
Total 99 26 25 25 23
Quantitative levels of KRAS mutations in plasma
DC 11 5 (56%) 2 (29%) 4 (40%) 0 (0%)a P ¼ 0.16a
PD 21 4 (44%) 5 (71%) 6 (60%) 6 (100%)
Total 32 9 7 10 6
NOTE: Quartiles (generated on the basis of the total cohort) were used for grouping of the patients and analyzed by c2 test.
Abbreviation: Q, quartile.
aWhen dichotomizing the KRASmutant group by the 75% quartile, a signiﬁcantly higher rate of DC was revealed in the patients with
level below 75% (P ¼ 0.049); see text.
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cfDNA     N* (%) median PFS in mo (95% CI)
<25% --      26 (25)              5.9 (4.2–7.7)
25%–50% -    27 (26)          4.8 (2.3–8.4) 
50%–75% -    26 (25)              2.3 (2.1–4.2) 
>75%  -       26 (25)             2.1 (1.9–2.8) 
Log-rank P = 0.0043
cfDNA    N* (%) median PFS in mo (95% CI)
<75% --   79 (75)        4.4 (2.8–6.0) 
>75% -    26 (25)        2.1 (1.9–2.8) 
Log-rank P = 0.0015, HR = 0.51 (95% CI, 0.29–0.88) 
cfDNA     N* (%) median 0S in mo (95% CI)
<25% --      26 (25)          14.5 (12.8–19.5)
25%–50% -    27 (25)         9.4 (5.7–11.5) 
50%–75% -    27 (25)             5.9 (4.5–9.0) 
>75%  -       26 (25)             3.6 (3.3–4.5) 
Log-rank P = 0.0000 
cfDNA       N (%) median OS in mo (95% CI)
<75% --       80 (76)       10.4 (7.3–12.8)
>75% -        26 (25)       3.6 (3.3–4.5) 
Log-rank P = 0.0000, HR = 0.32 (95% CI, 0.17–0.61) 
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pmKRAS      N (%) median PFS in mo (95% CI)
<25%  --       9 (26)       4.8 (1.2–5.9)
25%–50%  –     9 (26)        2.1 (2.0–2.8)
50%–75% -     10 (29)       2.3 (2.1–2.8) 
>75% -        7 (20)        1.8 (1.3–1.8) 
Log-rank P = 0.018 
pmKRAS    N (%) median PFS in mo (95% CI)
<75% --     28 (80)     2.3 (2.1–4.1)
>75% -       7  (20)     1.8 (1.3–1.8) 
Log-rank P = 0.008, HR = 0.36 (95% CI, 0.11–1.21) 
pmKRAS   N* (%) median OS in mo (95% CI)
<25% --       9 (26)               9.8 (5.8–13.0)
25%–50% -      9 (26)          4.7 (2.4–4.8) 
50%–75% -    10 (29)             4.7 (2.8–6.5) 
>75% -        7 (20)              2.1 (1.3–3.6) 
Log-rank P = 0.0008 
pmKRAS          N (%) median OS in mo (95% CI)
<75% --        28 (80)          5.0 (4.7–7.1)
>75% -           7 (20)          2.1 (1.3–3.6) 
Log-rank P = 0.0005, HR = 0.27 (95% CI, 0.07–1.05) 
Figure 2. Kaplan–Meier survival curves and log-rank test according to plasma levels of cfDNA and KRASmutations. The sample size for survival analysis was
limited to 105 patients because of invalid inclusion date of one patient and no blood sample available in 2 patients. KRAS mutations were detected in 35
patients. The sum of percentagesmay not be 100%because of rounding of data. HRs are only presented for data with one chosen cutoff point for analysis. (P
values were not corrected for multiple comparisons.)
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levels had been revealed. With this in mind, an isolated
multivariate analysis including pmKRAS levels grouped as
quartiles, PS, and number of metastatic sites confirmed the
independent prognostic value of pmKRAS (data not
shown). In brief, high levels of cfDNA and/or pmKRAS
were both strong predictors of a poor outcome.
Discussion
The present study contributes to our knowledge in 3
major aspects: the importance of circulating nucleic acids,
the quantitative measures of tumor-specific KRASmutation
alleles in plasma, and the possibility of improved selection
of therapy in mCRC by aids of the above markers.
The cfDNA inplasma frompatientswith cancer originates
from normal nonmalignant cells as well as necrotic and
apoptotic tumor cells (21), but neither the origin nor fate of
the circulating DNA is fully explored (18). A recent review
has summarized the few older clinical studies in CRC, but
although the results were promising, the studies were small
and primarily based on pre/post-surgical measurements or
comparison with healthy individuals.
We report a correlation between the quantitative mea-
sures of cfDNA and the tumor-specific KRAS mutation in
plasma, which has led us to hypothesize that the increasing
levels of cfDNA in patients with cancer are primarily of
tumor origin. The cfDNA may therefore have its greatest
potential in advanced disease.
pmKRAS analysis may help overcome some of the obvi-
ous limitations of tissue analysis forKRASmutations, which
are underlined in a recent review addressing KRAS for
clinical oncological practice (22). Tissue availability and
selection of specimens with a sufficient number of tumor
cells together with tumor heterogeneity are the major chal-
lenges affecting the quality and liability of DNA extracted.
We found a high concordance between KRAS status in
primary tumor and plasma (detection rate of 78% and
overall concordance of 91%), which is supported by the
literature. Lecomte and colleagues reported that the detec-
tion rate of mutations in the peripheral blood ranged
between 9% (3 of 16) and 100% (5 of 5). However, most
prior studies have included a very low number of patients
(18). Recently, Yen and colleagues investigated 76 patients
using a different method and found a detection rate similar
to that of our study (84.4%; ref. 23). The few disconcordant
results from our study should be further investigated.
No conclusion can be drawn from our data about pBRAF
detectionbecause of the low sample size andmarginally low
frequency, compared with the literature (24, 25), which
suggest a possible selection bias.
Wehave presented a feasible alternativemethod forKRAS
testing in plasma and, more importantly, explored the
potential value of quantification of the mutated alleles in
the clinical setting. We are not aware of similar studies that
can be used for direct comparison. In general, patients with
a high level of pretreatment pmKRAS had a poor prognosis,
compared with the subgroup of patients harboring KRAS
mutations at low levels, who achieved a prolonged stabi-
lization of disease. We present data indicating that it may
not only be the KRAS status itself but rather the quantitative
amount of this mutation that influences the disease behav-
ior. Consequently, a quantitative measure at baseline will
potentially help to select patients with primary KRAS dom-
inant disease, who have undetectable or very low levels of
the mutation and therefore potentially could benefit from
anti-EGFR therapy. Testing in other clinical settings will
reveal whether this solely applies to anti-EGFR therapy, but
we find it likely that the high levels reflect aggressive disease
behavior.
Of broader interest are our results showing that the
cfDNA quantitative levels were related to outcome in terms
of response, PFS, andOS regardless of the cutoff point used.
Table 4. Multivariate Cox regression analysis of PFS and OS
PFS OS
Variables HR (95% CI) P HR (95% CI) P
cfDNA quartile (1–4)a 1.3 (1.1–1.6) 0.005 1.7 (1.4–2.1) <0.00001
PSa 1.3 (0.9–1.8) 0.11 1.5 (1.1–2.2) 0.014
KRAS status in tumor
Wild-typeb 1 <0.00001 1 0.047
Mutation 2.7 (1.7–4.4) 1.6
Number of metastatic sites
1–2b 1 0.0024 1 0.001
>2 2.0 (1.3–3.2) 2.2 (1.4–3.6)
Anatomic site
Colonb — — 1 0.087
Rectum 0.7 (0.4–1.06)
aEntered in the model as numeric variables. The quartiles (1–4) were used for grouping of cDNA levels, and HRs consequently
correspond to one-step increase in quartiles. PS was divided into 0, 1, and 2. (No patients with PS 3 were included in the study.)
bReference group.
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When entered in amultivariate Coxmodel, an independent
prognostic value of cfDNAwas confirmed. To the best of our
knowledge, there are no other studies investigating the
quantitative levels of cfDNA and in a similar clinical setting.
Interesting observations were conducted by Diehl and
colleagues who measured cfDNA with patient-specific
mutations such as APC, KRAS, and PIK3CA in consecutive
samples during follow-up after surgery and found a corre-
lation between post-surgical mutation levels and the out-
come (15).
The present sample size did not allow for a conclusion
of the mutual contribution of the pmKRAS and cfDNA
levels. Quantification of KRAS in plasma is limited to the
subgroup of patients with KRAS mutant disease. Our
results of cfDNA should be investigated in larger sample
sizes and different clinical settings to clarify its full poten-
tial as a marker in CRC. It is questionable whether
pmKRAS analysis will provide additional predictive or
prognostic information to cfDNA quantification in this
specific setting because of the strong correlation and
thereby surrogate effect of the 2 markers. However, our
data suggest that patients with a low KRAS allele count at
baseline could still benefit from the treatment, but at
present, these patients are not considered candidates for
EGFR inhibitor treatment because they harbor KRAS
mutant disease. We therefore suggest that pmKRAS can
be used as supplement to tissue KRAS analysis as a tool for
selection prior to treatment and the predictive value of
this marker is further investigated in prospective studies
in KRAS mutant cohorts.
In conclusion, KRAS mutations can be detected in the
peripheral blood as an alternative to tissue analysis, and
quantitative levels of cfDNA and pmKRAS were both asso-
ciated to clinical outcome of third-line treatment of mCRC.
Quantification of cfDNA and KRAS mutations in the
peripheral circulation has potential value as a clinical tool
for more individualized pretreatment testing and could
improve selection of therapy. Further studies along that
line seem justified.
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